Cargando…
N-Acetylcysteine to Combat COVID-19: An Evidence Review
The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly...
Autores principales: | Shi, Zhongcheng, Puyo, Carlos A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649937/ https://www.ncbi.nlm.nih.gov/pubmed/33177829 http://dx.doi.org/10.2147/TCRM.S273700 |
Ejemplares similares
-
N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions
por: Izquierdo-Alonso, José Luis, et al.
Publicado: (2022) -
Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia
por: Willborn, Robert J., et al.
Publicado: (2019) -
N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence
por: Ooi, Soo Liang, et al.
Publicado: (2018) -
Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset
por: Lana, José Fábio Santos Duarte, et al.
Publicado: (2021) -
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence
por: Wong, Kon Ken, et al.
Publicado: (2021)